Trade Mark Journal No.2025/002 10 January 2025

UK00004139295 19 December 2024 (5,42)

Image for mark UK00004139295 CG ONCOLOGY ONCOLYTIC IMMUNOTHERAPY
Class 5
Pharmaceutical products for the treatment of cancer; pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing.
Class 42
Pharmaceutical research and development; Providing medical and scientific research information in the fields of oncology, autoimmune disorders, immunotherapy, immunotherapeutics, biotechnology, biopharmaceuticals, pharmaceuticals, therapies, diseases, and disorders.

CG Oncology, Inc.

Representative: Kilburn & Strode LLP